GleamWall
中文EN

RGBP Regen BioPharma Inc

Pharmaceutical Preparations · OTC · SEC CIK 1589150 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.0%
TTM net income YoY-54.5%
TTM EPS YoY77.8%
Revenue 3-yr CAGR15.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-339.8%
Net margin-501.4%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-489.7%
ROIC (approx.)—
Asset turnover0.98x

Leverage & solvency

Liabilities / assets2,144.0%
Debt / equity—
Current ratio0.05x
Interest coverage-4.72x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-305.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$59,065$59,065$59,065$59,366$59,065$59,065$59,065$59,366
R&D expense$0$2,216$210,000$11,725$0$0$0$33,524
SG&A expense$13,842$32,104$231,925$17,749$30,697$13,348$13,317$20,622
Operating income$24,528-$153,709-$551,624-$123,055-$40,756-$113,349-$61,378-$85,402
Interest expense$30,360$27,388$26,553$85,967$24,638$22,329$25,352$20,063
Pretax income-$637,785$991,927-$967,853-$572,469-$167,292-$19,354-$515,384-$270,748
Income tax$0$0$0$0$0$0$0—
Net income-$637,785$991,927-$967,853-$572,469-$167,292-$19,354-$515,384-$65,902
EPS (basic)0.000.00-0.01—-0.010.00-0.13—
EPS (diluted)0.000.00-0.01—-0.010.00-0.13—
Weighted avg. shares (diluted)615.56M184.94M99.61M—23.75M21.55M4.11M—
Balance sheet
Cash & equivalents$239$271$4,578$69,555$1,761$1,761$135$716
Receivables$287,147$259,723$232,298$204,873$177,147$149,723$122,298$94,873
Current assets$287,587$260,194$237,076$274,628$179,108$151,749$173,683$143,351
Total assets$287,587$260,194$237,076$274,628$196,841$169,482$191,416$161,084
Current liabilities$6.17M$5.62M$6.81M$6.56M$6.01M$5.87M$5.87M$5.38M
Total liabilities$6.17M$5.62M$6.81M$6.56M$6.01M$5.87M$5.87M$5.38M
Shareholders' equity-$5.88M-$5.36M-$6.57M-$6.28M-$5.82M-$5.70M-$5.68M-$5.22M
Shares outstanding1.13B351.44M108.05M39.37M31.55M21.55M21.55M5.26M
Cash flow statement
Operating cash flow-$24,069-$63,234-$197,941-$160,005-$55,977-$101,230-$66,379-$207,290
Financing cash flow$24,037$58,926$132,964$227,799$55,976$102,856$65,799$146,157
Stock-based compensation———————$10,724

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.